{
    "root": "34160c45-6041-6436-e063-6294a90adef3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phenytoin",
    "value": "20250501",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "ALUMINUM OXIDE",
            "code": "LMI26O6933"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "PHENYTOIN",
            "code": "6158TKW0C5"
        }
    ],
    "indications": "Phenytoin chewable tablets are indicated for the treatment of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.",
    "contraindications": "NOT FOR ONCE-A-DAY DOSING ( 2.1 ) Adult starting dose in patients who have received no previous treatment is two phenytoin chewable tablets three times a day, with dose adjustments as necessary. For most adults, the satisfactory maintenance dose will be six to eight phenytoin chewable tablets daily; an increase to twelve phenytoin chewable tablets daily may be made, if necessary. ( 2.2 ) Pediatric starting dose is 5 mg/kg/day in two to three equally divided doses, with dosage adjustments as necessary, up to a maximum of 300 mg daily. Maintenance dosage is 4 mg/kg/day to 8 mg/kg/day. ( 2.3 ) Serum blood level determinations may be necessary for optimal dosage adjustments—the clinically effective serum total concentration is 10 mcg/mL to 20 mcg/mL (unbound phenytoin concentration is 1 mcg/mL to 2 mcg/mL). ( 2.4 )",
    "warningsAndPrecautions": "Phenytoin Chewable Tablets USP, 50 mg are yellow, uniform to slightly mottled, round normal convex tablets, scored and engraved with \"T\" above the score and \"50\" below the score on one side and plain on the other side. The tablets are banana flavored. They are supplied as follows:\n                  NDC: 70518-0841-00\n                  NDC: 70518-0841-01\n                  NDC: 70518-0841-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Phenytoin chewable tablets are contraindicated in patients with:\n                  \n                     A history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.5)]\n        \n  \n   . Reactions have included angioedema.\n       \n \n  \n                     A history of prior acute hepatotoxicity attributable to phenytoin \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.8)]\n        \n  \n   .\n       \n \n  \n                     Coadministration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors."
}